The London-based biomaterials startup secured $15m from investors including Alter Equity and JamJar Investments to expand its manufacturing network in the United States and Europe.
"Shellworks represents exactly the kind of innovation we need to see in the materials economy. They’re not just creating a better material, they’re building the infrastructure to make it accessible at scale. That’s what will drive real change and contribute to the plastic-free economy we are supporting at alter equity."
The financing round was led by Soulmates Ventures with backing from several new and existing investors.
"Antiverse is tackling one of the most technically demanding problems in drug discovery. The team’s ability to reduce the development time for de novo therapeutic-grade antibodies in a defined domain to under four months is a significant scientific and operational achievement. This capability, combined with the AI-driven design and in-house labs, positions Antiverse on track to become a global leader and the go-to developer of antibody therapies for the most elusive disease targets in medicine"
The funding will support Phase I clinical trials for the company lead antimicrobial candidate.
"We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections. This latest investment has enabled us a clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. I would like to thank the AMR Action Fund, as well as all of our existing investors and collaborators, for their support."
The Series A was led by GV with participation from Accel, Northzone, and other backers.
"Magic happens when companies get the exact technology they need. Enterprises are desperate to capitalize on the AI coding revolution, but nobody has built a product that reflects their reality – complex systems, strict standards, and global scale. SolveAI puts the power to build software directly in the hands of the people closest to the problems, without compromising security or compliance. Think about all the things you could achieve if your IT team could be everywhere at once: SolveAI makes this a reality."
The financing round was led by KB Partners alongside Koppenberg Management, Match Ventures, and private syndicates.
"This round allows us to scale what we know already works. We have strong consumer demand, proven technology, and growing adoption among professionals. These fresh funds will help us expand into new international markets, business models, and sports beyond basketball. Our new investors share our vision and understand how big the demand for our technology is, and we are ready to scale at speed,"
.png)
